Clinical Trials Logo

Clinical Trial Summary

This is a Phase II, open-label, single-arm, study, designed to evaluate the efficacy and safety of tenalisib in patients with metastatic TNBC, who have received at least one but not more than 3 prior therapies in a metastatic setting.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06189209
Study type Interventional
Source Rhizen Pharmaceuticals SA
Contact Prajak Barde, MD
Phone +41325800175
Email pjb@rhizen.com
Status Recruiting
Phase Phase 2
Start date March 4, 2024
Completion date March 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05383196 - Onvansertib + Paclitaxel In TNBC Phase 1/Phase 2
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Withdrawn NCT03554109 - QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine Phase 2
Recruiting NCT05088057 - Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer Phase 2
Recruiting NCT05949021 - OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer Phase 2
Recruiting NCT05891171 - Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers Phase 1
Recruiting NCT03855358 - A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC) Phase 1
Terminated NCT02698176 - A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006) Phase 1
Completed NCT02819518 - Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) Phase 3
Terminated NCT03549000 - A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. Phase 1
Completed NCT02178722 - Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers Phase 1/Phase 2
Terminated NCT04424641 - A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors Phase 1/Phase 2
Terminated NCT03742349 - Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). Phase 1
Recruiting NCT03746431 - A Phase 1/2 Study of [225Ac]-FPI-1434 Injection Phase 1/Phase 2
Recruiting NCT05555706 - Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer Phase 2/Phase 3
No longer available NCT03123211 - Expanded Access to Veliparib